Table 1 Study population.
From: Estrogen hormone replacement therapy in incidental intracranial meningioma: a growth-rate analysis
no-HRT | N | (%) | Mean | ± SE | (min–max) | p value‡ |
|---|---|---|---|---|---|---|
Age (years) | ||||||
At diagnosis | 40 | (100) | 62.1 | 1.9 | (37.0–93.2) | 0.98 |
At end of follow up | 40 | (100) | 68.9 | 1.8 | (47.2–95.6) | 0.57 |
Follow up time (years) | 40 | (100) | 6.8 | 0.6 | (1.2–16.4) | 0.061 |
HRT duration (years) | 40 | (100) | 5.0 | 0.7 | (0.5–22.0) | – |
Started and finished before diagnosis | 11 | (27.5) | 3.7 | 12.8 | (1.0–13.4) | – |
Started after diagnosis | 18 | (45) | 3.2 | 7.3 | (0.5–9.6) | – |
Started before, finished after diagnosis | 11 | (27.5) | 9.4 | 1.5 | (1.4–22.0) | – |
Route | ||||||
Oral/transdermal | 25 | (62.5) | – | – | – | – |
Vaginal | 12 | (30) | – | – | – | – |
Both | 3 | (7.5) | – | – | – | – |
Estrogen agent | ||||||
Estradiol | 25 | (62.5) | – | – | – | – |
Conjugated estrogens | 11 | (27.5) | – | – | – | – |
Multiple, other | 4 | (10) | – | – | – | – |
Other characteristics | ||||||
Body-Mass Index (kg/m2) | 40 | (100) | 26.3 | 0.9 | (18.0–47.0) | 0.043* |
Number of children (parity) | 39 | (97.5) | 2.1 | 0.2 | (0–6) | 0.65 |
Radiographic characteristics (qualitative) | ||||||
Calcified | 18 | (50) | – | – | – | 0.35 |
Perilesional edema | 3 | (7.5) | – | – | – | 0.54 |
T2-hyperintense | 15 | (38.5) | – | – | – | 0.30 |
no–HRT | N | (%) | Mean | ± SE | (min–max) | |
|---|---|---|---|---|---|---|
Age (years) | ||||||
At diagnosis | 80 | (100) | 62.2 | 1.3 | (36.7–96.4) | – |
At end of follow up | 80 | (100) | 67.5 | 1.5 | (38.8–97.2) | – |
Follow up time (years) | 80 | (100) | 5.3 | 0.4 | (0.6–14.4) | – |
Other characteristics | ||||||
Body-Mass Index (kg/m2) | 80 | (100) | 29.1 | 0.9 | (19.6–57.3) | – |
Number of children (parity) | 56 | (70) | 2.0 | 0.2 | (0–6) | – |
Radiographic characteristics (qualitative) | ||||||
Calcified | 37 | (56.1) | – | – | – | – |
Perilesional edema | 5 | (6.3) | – | – | – | – |
T2-hyperintense | 35 | (43.8) | – | – | – | – |
